U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H24N2O2S.H3NO3S
Molecular Weight 453.575
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HYCANTHONE SULFAMATE

SMILES

NS(O)(=O)=O.CCN(CC)CCNC1=CC=C(CO)C2=C1C(=O)C3=C(S2)C=CC=C3

InChI

InChIKey=XKXSMHTUJNQUOW-UHFFFAOYSA-N
InChI=1S/C20H24N2O2S.H3NO3S/c1-3-22(4-2)12-11-21-16-10-9-14(13-23)20-18(16)19(24)15-7-5-6-8-17(15)25-20;1-5(2,3)4/h5-10,21,23H,3-4,11-13H2,1-2H3;(H3,1,2,3,4)

HIDE SMILES / InChI

Molecular Formula C20H24N2O2S
Molecular Weight 356.482
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula H3NO3S
Molecular Weight 97.094
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Hycanthone is a thioxanthene derivative of lucanthone with anti-schistosomal activity and potential antineoplastic activity. It was clinically available for the treatment of human schistosomiasis. Anti-helmintic action relies on its ability to inhibit worm monoamine oxidase and cholinesterases. Hycanthone produced immediate side effects such as hepatotoxicity and gastrointestinal disturbances, and was consequently withdrawn. Hycanthone inhibits apurinic endonuclease-1 (APE1) by direct protein binding. Hycanthone was used in the 1980s as antitumor agents, it was pulled out of Phase II trials.

Originator

Curator's Comment: reference retrieved from www.drugfuture.com/chemdata/hycanthone.html

Approval Year

PubMed

PubMed

TitleDatePubMed
Long-term hepatocellular effects of hycanthone and of two other anti-Schistosomal drugs in mice infected with Schistosoma mansoni.
1976 Jun
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005 Jun
The NIH-NIAID schistosomiasis resource center.
2008 Jul 30
Mefloquine--an aminoalcohol with promising antischistosomal properties in mice.
2009
Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoni.
2009 Aug 18
Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening.
2009 Jul 14
RNA interference in Schistosoma mansoni schistosomula: selectivity, sensitivity and operation for larger-scale screening.
2010 Oct 19
Identification of novel p53 pathway activating small-molecule compounds reveals unexpected similarities with known therapeutic agents.
2010 Sep 27
Screening of a chemical library reveals novel PXR-activating pharmacologic compounds.
2015 Jan 5
Patents

Patents

Sample Use Guides

Human schistosomiasis: single intramuscular dose (3.0, 2.5, 2.0, 1.5, and 1.0 mg/kg body weight).Unresectable pancreatic cancer: hycanthone was administered 60 mg/m2 intravenously within 2 to 4 hr during each day of the 5-day course of infusions during the first and fifth weeks of radiation therapy.
Route of Administration: Other
In Vitro Use Guide
Hycanthone stimulates motor activity of Schistosoma mansoni at concentrations of 10(-6) to 10(-5) M, and partially blocks the paralytic effects of carbachol and physostigmine.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:36:49 GMT 2023
Edited
by admin
on Fri Dec 15 15:36:49 GMT 2023
Record UNII
6QS8DNR44V
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
HYCANTHONE SULFAMATE
Common Name English
SULFAMIC ACID, COMPD. WITH 1-((2-(DIETHYLAMINO)ETHYL)AMINO)-4-(HYDROXYMETHYL)-9H-THIOXANTHEN-9-ONE (1:1)
Systematic Name English
Code System Code Type Description
CAS
23282-51-1
Created by admin on Fri Dec 15 15:36:49 GMT 2023 , Edited by admin on Fri Dec 15 15:36:49 GMT 2023
PRIMARY
CAS
27948-13-6
Created by admin on Fri Dec 15 15:36:49 GMT 2023 , Edited by admin on Fri Dec 15 15:36:49 GMT 2023
NON-SPECIFIC STOICHIOMETRY
EPA CompTox
DTXSID20182231
Created by admin on Fri Dec 15 15:36:49 GMT 2023 , Edited by admin on Fri Dec 15 15:36:49 GMT 2023
PRIMARY
FDA UNII
6QS8DNR44V
Created by admin on Fri Dec 15 15:36:49 GMT 2023 , Edited by admin on Fri Dec 15 15:36:49 GMT 2023
PRIMARY
PUBCHEM
31830
Created by admin on Fri Dec 15 15:36:49 GMT 2023 , Edited by admin on Fri Dec 15 15:36:49 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY